Enclomiphene Therapy

TRT (testosterone replacement therapy) introduces exogenous testosterone directly into your body, which raises testosterone levels but suppresses your pituitary gland's natural LH and FSH production — leading to testicular atrophy and significantly reduced sperm production. Enclomiphene takes the opposite approach: it stimulates your pituitary to increase its own LH and FSH output, which in turn signals your testes to produce more testosterone naturally. The result is higher testosterone levels while maintaining — or even improving — testicular function and sperm production.

Yes, and this is one of the primary reasons men choose enclomiphene over TRT. Because enclomiphene increases LH and FSH — the hormones that drive sperm production — it supports fertility rather than suppressing it. Men who want to optimize their testosterone levels while preserving their ability to conceive are ideal candidates for enclomiphene therapy. If fertility is a concern, always inform your provider before starting any testosterone-related treatment.

The degree of testosterone increase varies by individual, but clinical studies have shown that enclomiphene can increase total testosterone by 150-400 ng/dL in most men with secondary hypogonadism. Starting from a baseline of, say, 250 ng/dL, many men reach levels in the 400-600 ng/dL range. Results depend on the health and responsiveness of your testes, your baseline hormone levels, and the dose prescribed. We monitor your testosterone, LH, FSH, and estradiol levels and adjust dosing to achieve optimal results.

The ideal enclomiphene candidate is a man with low testosterone (secondary hypogonadism) who wants to raise his levels while preserving fertility. This includes younger men who plan to have children, men in relationships where future conception is possible, and men who prefer a more conservative approach before committing to TRT. Enclomiphene works best in men with secondary hypogonadism — where the issue is insufficient pituitary signaling, not primary testicular failure. Men with primary hypogonadism (damaged or absent testes) will not respond to enclomiphene.

Enclomiphene is generally well-tolerated. The most commonly reported side effects include headache, nausea, and occasional mood changes as hormone levels adjust. Because enclomiphene can increase estrogen levels alongside testosterone (since more testosterone means more substrate for aromatization), some men may experience estrogen-related effects such as mild water retention or nipple sensitivity. We monitor estradiol levels and can prescribe an aromatase inhibitor if estrogen rises excessively. Serious side effects are rare at therapeutic doses.

Most men begin to see improvements in testosterone levels within two to four weeks of starting treatment. Symptom improvement — better energy, mood, libido, and cognitive function — typically follows within four to eight weeks. We check blood work at the four to six week mark to assess hormone levels and adjust the dose if needed. Maximum benefit is usually achieved within two to three months of optimized dosing.